Shipping of therapeutic somatic cell products

Cytotherapy

Volumn 13, Issue 2, 2011, Pages 201-213

  Whiteside, Theresa L ^a   Griffin, Deborah L ^a   Stanson, Joanna ^a   Gooding, William ^a   McKenna, David ^b   Sumstad, Darin ^b   Kadidlo, Diane ^b   Gee, Adrian ^c   Durett, April ^c   Lindblad, Robert ^d   Wood, Deborah ^d   Styers, David ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d EMMES CORPORATION   (United States)

Author keywords

Cell products for therapy; Somatic cell products; Transport of somatic cells; Validation of cell shipping

Indexed keywords

APHERESIS; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL FUNCTION; CELL MATURATION; CELL THERAPY; CELL VIABILITY; CRYOPRESERVATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SHIPPING; SOMATIC CELL;

EID: 78751562035     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.506507     Document Type: Article

References (18)

1. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9: 704-16.
2. Brentjens RJ. Cellular therapies in acute lymphoblastic leukaemia. Curr Opin Mol Ther. 2009;11:375-82.
3. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, Stassi G. Therapeutic implications of cancer initiating cells. Expert Opin Biol Ther. 2009;9:1005-16.
4. Garcia-Castro J, Trigueros C, Madrenas J, Perez-Simon JA, Rodriquez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modeling tool. J Cell Mol Med. 2008;12:2552-65.
5. Moroff G, Seetharaman S, Kurtz JW, Greco NJ, Mullen MD, Lane TA, Law P. Retention of cellular properties of PBPCs following liquid storage and cryopreservation. Transfusion. 2004;44:245-52.
6. Hubel A, Cariquist D, Clay M, McCullough J. Liquid storage, shipment, and cryopreservation of cord blood. Transfusion. 2004;44:518-25.
7. Janssen WE, Lee CE. Shipping of bone marrow. In: Areman EM, Deeg HJ, Sacher RA. Bone Marrow and Stem Cell Processing: A Manual of Current Techniques. Philadelphia: FA Davis Company; 1992. p. 445 - 8.
8. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625-32.
9. Whiteside TL. Generation and characterization of human dendritic cells for therapy. In: Areman EM, Loper K. Cellular Therapy: Principles, Methods, and Regulations. Bethesda: AABB; 2009. p. 467 - 72.
10. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specifi c cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942-9.
11. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui J-G, Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells. 2002;6: 530-41.
12. Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal. 1990;4: 102-14.
13. Butterfi eld LH, Gooding W, Whiteside TL. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother. 2008;31:89-100.
14. Kenward MG, Roger JH. Small sample inference for fi xed effects from restricted maximum likelihood. Biometrics. 1997;53:983-97.
15. Searle S, Speed T, Milliken G. Population marginal means in the linear model; an alternative to least squares means. Am Stat. 1980;34:216-21.
16. Edwards D, Berry J. The effi ciency of simulation-based multiple omparisons. Biometrics. 1987;43:913-28.
17. Singh P, Williams DJ. Cell therapies: realizing the potential of this new dimension to medical therapeutics. J Tissue Eng Regen Med. 2008;2:307-19.
18. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long term outcome of EBV specifi c T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-935 .